Using a treatment diary to improve the medication adherence in patients with chronic myeloid leukaemia

Abstract

Purpose

The aim of this study was to verify whether the distribution of a treatment diary by a pharmacist could influence the adherence to oral treatment with imatinib, nilotinib, and dasatinib in patients with chronic myeloid leukaemia.

Methods

The level of adherence was calculated using the received daily dose/prescribed daily dose ratio and compared between patients who used a diary and those who did not.

Results

Forty-four (35.8%) of 123 patients with chronic myeloid leukaemia completed the diary: 20 (45.4%) receiving imatinib, 17 (38.6%) receiving nilotinib, and seven (15.9%) receiving dasatinib. Treatment adherence with the diary calculated using received daily dose/prescribed daily dose method was 93.6% (imatinib 94.9%, nilotinib 91.1%, and dasatinib 95.8%). Adherence during the period without a diary was 86.5% (84.9, 87.4, and 90%). Adherence was significantly greater with than without a diary (p < 0.0001).

Conclusions

The findings of this study that, in the case of chronic diseases, direct pharmacist–patient contact is important in order to maintain high levels of adherence, and a treatment diary is a valid means of doing this. According to these data, it is necessary to support similar patient-oriented programmes in order to ensure high levels of adherence and optimize drug management.

Keywords

Medication adherence chronic myeloid leukaemia imatinib dasatinib nilotinib

Get full access to this article

View all access options for this article.

References

World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization, http://apps.who.int/iris/bitstream/10665/42682/1/9241545992.pdf (2003, accessed 30 June 2017).

Gellad

Grenard

Marcum

. A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. Am J Geriatr Pharmacother 2011; 9: 11–23.

Alvarez Payero

Martínez López de Castro

Ucha Samartín

et al.

Medication non-adherence as a cause of hospital admissions. Farm Hosp 2014; 38: 328–333.

Seabury

Gupta

Philipson

et al.

PhRMA medication adherence advisory council. Understanding and overcoming barriers to medication adherence: a review of research priorities. J Manag Care Spec Pharm 2014; 20: 775–783.

Brown

Bussell

Dutta

et al.

Medication adherence: truth and consequences. Am J Med Sci 2016; 351: 387–399.

Brown

Bussell

. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304–314.

Briesacher

Andrade

Fouayzi

et al.

Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437–443.

Rolnick

Pawloski

Hedblom

et al.

Patient characteristics associated with medication adherence. Clin Med Res 2013; 11: 54–65.

Zhao

Zabriski

Bertram

. Associations between statin adherence level, health care costs, and utilization. J Manag Care Spec Pharm 2014; 20: 703–713.

10.

Yeaw

Benner

Walt

et al.

Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009; 15: 728–740.

11.

Zelko

Klemenc-Ketis

Tusek-Bunc

. Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies. Mater Sociomed 2016; 28: 129–132.

12.

Iuga

McGuire

. Adherence and health care costs. Risk Manag Healthc Policy 2014; 7: 35–44.

13.

Kardas

Lewek

Matyjaszczyk

. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol 2013; 4: 91–91.

14.

Sorensen

Pestka

Brummel

et al.

Seeing the forest through the trees: improving adherence alone will not optimize medication use. J Manag Care Spec Pharm 2016; 22: 598–604.

15.

Shingler

Bennett

Cramer

et al.

Treatment preference, adherence and outcomes in patients with cancer: literature review and development of a theoretical model. Curr Med Res Opin 2014; 30: 2329–2341.

16.

Coleman

Limone

Sobieraj

et al.

Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012; 18: 527–539.

17.

Calvo-Cidoncha

González-Bueno

Almeida-González

et al.

Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients. J Manag Care Spec Pharm 2015; 21: 153–157.

18.

Mendys

Zullig

Burkholder

et al.

Medication adherence: process for implementation. Patient Prefer Adherence 2014; 8: 1025–1034.

19.

McCue

Lohr

Pick

. Improving adherence to oral cancer therapy in clinical practice. Pharmacotherapy 2014; 34: 481–494.

20.

Shuler

. Approaches to improve adherence to pharmacotherapy in patients with schizophrenia. Patient Prefer Adherence 2014; 8: 701–714.

21.

van Boven

Stuurman-Bieze

Hiddink

et al.

Medication monitoring and optimization: a targeted pharmacist program for effective and cost-effective improvement of chronic therapy adherence. J Manag Care Spec Pharm 2014; 20: 786–792.

22.

National Collaborating Centre for Primary Care. Medicines adherence: involving patients in decisions about prescribed medicines and supporting adherence, London: NICE, 2009.

23.

Marin

Bazeos

Mahon

et al.

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381–2388.

24.

Ibrahim

Eliasson

Apperley

et al.

Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733–3736.

25.

García-Queiruga

Martínez-López

Martín-Herranz

et al.

Study on adherence to treatment with imatinib in chronic myeloid leukaemia and its association with therapeutic response. Farm Hosp 2016; 40: 141–149.

26.

Santoleri

Lasala

Ranucci

et al.

Medication adherence to tyrosine kinase inhibitors: 2-year analysis of medication adherence to imatinib treatment for chronic myeloid leukemia and correlation with the depth of molecular response. Acta Haematol 2016; 136: 45–51.

27.

Urquhart

. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345–356.

28.

McHorney

. The Adherence Estimator: a brief, proximal screener for patient propensity to adhere to prescription medications for chronic disease. Curr Med Res Opin 2009; 25: 215–238.

29.

Svarstad

Chewning

Sleath

et al.

The brief medication questionnaire: a tool for screening patient adherence and barriers to adherence. Patient Educ Couns 1999; 37: 113–124.

30.

Morisky

Green

Levine

. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24: 67–74.

31.

Gardner

Sharma

Peng

et al.

Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS 2008; 22: 75–82.

32.

Viana

Laszczynska

Mendes

et al.

Medication adherence to specific drug classes in chronic heart failure. J Manag Care Spec Pharm 2014; 20: 1018–1026.

33.

Sidorkiewicz

Tran

Cousyn

et al.

Development and validation of an instrument to assess treatment adherence for each individual drug taken by a patient. BMJ Open 2016; 6: e010510–e010510.

34.

McCormack

Horne

Sheather

. Clinical applications of visual analogue scales: a critical review. Psychol Med 1988; 18: 1007–1019.

35.

Aljumah

Hassali

. Impact of pharmacist intervention on adherence and measurable patient outcomes among depressed patients: a randomised controlled study. BMC Psychiatry 2015; 15: 219–219.

36.

Ganguli

Clewell

Shillington

. The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review. Patient Prefer Adherence 2016; 10: 711–725.

37.

Varming

Hansen

Andrésdóttir

et al.

Empowerment, motivation, and medical adherence (EMMA): the feasibility of a program for patient-centered consultations to support medication adherence and blood glucose control in adults with type 2 diabetes. Patient Prefer Adherence 2015; 9: 1243–1253.

38.

Whisenhunt

. Social work and medical care: electronic reminders to address adherence. J Evid Based Soc Work 2014; 11: 248–255.

39.

McMullen

Safford

Bosworth

et al.

Patient-centered priorities for improving medication management and adherence. Patient Educ Couns 2015; 98: 102–110.

40.

Chummun

Boland

. How patient beliefs affect adherence to prescribed medication regimens. Br J Nurs 2013; 22: 270–276.

41.

Aronson

. Balanced prescribing – principles and challenges. Br J Clin Pharmacol 2012; 74: 566–72.

42.

Santoleri

Sorice

Lasala

et al.

Patient adherence and persistence with Imatinib, Nilotinib, Dasatinib in clinical practice. PLoS One 2013; 8: e56813–e56813.

43.

Amitai

Leader

Raanani

. Adherence to tyrosine kinase inhibitors in chronic myeloid leukemia: the challenge that lies ahead. Acta Haematol 2016; 136: 43–44.

44.

Chesney

Ickovics

Chambers

et al.

Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12: 255–266.

45.

Wagner

. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STDS 2002; 16: 599e608–599e608.

46.

Stone

Shiffman

Schwartz

et al.

Patient compliance with paper and electronic diaries. Control Clin Trials 2003; 24: 182e199–182e199.

47.

Khair

. Compliance, concordance and adherence: what are we talking about? Haemophilia 2014; 20: 601–603.

48.

Gorenoi

Schönermark

Hagen

. Interventions for enhancing medication compliance/adherence with benefits in treatment outcomes. GMS Health Technol Assess 2008; 3: Doc14–Doc14.